Mind Cure Health 
Set To Disrupt $225* Billion Industry 

“May transform mental health care” - Fortune**

One of the greatest shake-ups in the healthcare industry is underway. 

Top medical researchers have begun to focus on a unique, controversial, and potentially highly effective treatment for some of the world’s most complex and costly mental health conditions including addiction, depression, and PTSD.

Some of the world’s most prominent and successful Silicon Valley investors are backing it with hundreds of millions of dollars. 

One prominent analyst recently estimated the total size of this opportunity at $100 Billion.1

And today’s featured company, Mind Cure (OTC: MCURF | CSE: MCUR), is a small company that has positioned itself at the center of it all. 

And with a current market value of just over US$25 million2, this small upstart company has a lot of room to grow to catch up to its top competitors which have earned valuations of $1 billion and more. 

Mind Cure has already started the aggressive growth path with a few recent announcements and the markets are reacting. 

Mind Cure shares have steadily climbed as much as 200% since its Initial Public Offering (IPO) in September through to the start of December, but as you’ll see below, the company still has a lot of room to grow. 

This is an explosive situation, the window of opportunity is open, and now is the time to determine if it’s for you. 

First, let’s start at the beginning. 
Fortune Favors The Bold
New neuroscience medicines are shaping up to be a potential game-changer in the $225* billion-per-year mental health industry. 

Bloomberg sums up this radical opportunity in a piece that says  "investors beginning to flood this new market with capital, will Big Pharma join in"  from November 20203

A re-emerging interest in Neuroscience and medicinal compounds have been rediscovered by the scientific, medical and psychiatric communities as research reveals their capacity to help patients with a range of mental health maladies.

It’s more than a bit controversial, but historic research shows there’s real potential here.

And for investors looking for early-stage biotech stocks in rapidly growing sectors, Mind Cure (OTC: MCURF | CSE: MCUR), today’s featured company, has put itself at the heart of the neuroscience biotech boom.

But here’s the key. 

Mind Cure is still valued at a small fraction of some of the billion-dollar-plus “unicorns” that these biotechs stocks have already produced. 

READ: The Three Hottest Biotech Stocks That Every Investor Should Research

Big Money Backing Neuroscience Start-Ups

Top Investors Lining Up For Biotechs

Peter Thiel

Renowned Venture Capitalist

First investor in Facebook and early investor in Uber, AirBNB and many others. His fund committed major investment when COMPASS Pathways raised $80 Million to fund clinical research in medicinal benefits of psychoactive compounds. 

Kevin O’leary

Shark Tank Star

This CNBC ”Shark” originally founded and sold software provider The Learning Company for $4 billion. He now is an early investor in neuroscience company Mind Medicine [B] (OTCQB:MMEDF   CSE: MMED) 

Bruce Linton

Founder and Former CEO of Canopy Growth

Founder, early investor, and CEO of one of the earliest and largest legal cannabis companies in the world – Canopy Growth ($12.9 Billion NYSE: CGC). Mr. Linton is an early investor in Mind Medicine [C]  (OTCQB:MMEDF  CSE: MMED) 

Tim Ferriss

NYT Bestseller and Top Podcaster

Early investor Uber, FB, Twitter, Alibaba, Shopify is now directly funding research in psychoactive drug research as an alternative treatment for depression. Mr. Ferris donated $1 million to recent $30M phase 3 Trial progam. [D] 

Biotech Stocks are a classic “special situation.”

They’re targeted at an industry – mental healthcare – that’s overdue for innovation. 

Early indications from clinical research say it could, as Fortune Magazine says, “transform mental health care.”4

The research shows using these special medicinal compounds in a clinical setting could have a profoundly positive effect on mental health.

And they’ve earned the backing of the top Silicon Valley investors. 

For example, Peter Thiel, the first investor in Facebook (FB) and an early investor in Bitcoin and dozens of other tech giants, has backed two neuroscience companies. 

The first one he invested in, Compass Pathways (NASDAQ: CMPS), received a patent by the FDA for treatment-resistant depression4a

And after raising more than $100 million in an Initial Public Offering (IPO) in October 2020 to accelerate its research, Compass Pathways has a market value of more than $1.5 BILLION today. 

ATAI Life Sciences (privately held) is another company in this sector, backed in part by Peter Theil.

The company just raised $125 million from some of the world’s most notable venture capitalists.

If it follows the same route as Compass Pathways, it will IPO in 2021 and is thought to begin trading at a value well above $1 BILLION.6

Mind Medicine (OTC: MMEDF | CSE: MMED) is another leading neuroscience research company. 

Mind Medicine is backed by Shark Tank star Kevin O’Leary.

And it has soared in value this year. Today it's worth $1.6 BILLION.7
These early investors are making fortunes from it all. 

Take Mind Medicine (NEO: MMED | OTCQB: MMEDF) for instance.  

Its shares rose 1332% from lows earlier in Sept. 2020.


Numiness Wellness (CSE: NUMI | OTCQB: LKYSF) is another. 

Its shares have soared as much as 576% since bottoming out last summer.


Cybin Inc (NEO: CYBN | OTCQB: CLXPF) is another one which has taken off. 

Cybin shares have climbed as much as 223% in just about two months.


The sharp rise in these stocks is a clear indication something big is brewing here. 

But these are advanced companies with big funding. 

The best opportunity is looking to be in the small upstarts within the neuroscience sector. 

And it’s why we’re researching the companies which are in the same sector, but which haven’t run nearly as high. 

One of these companies which is still building up is Mind Cure (OTC: MCURF | CSE:MCUR).

Mind Cure (OTC: MCURF | CSE: MCUR) Has Room To Run In Neuroscience Race

Mind Cure is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of global mental health crisis.8

The company completed its IPO in September of 2020 and has been rapidly expanding with a focus on the five largest subsectors of the neuroscience market. 

Clinical Research

Mind Cure intends to be in a position take the information it learns from academic research and inquiry to investigate the clinical research potential of new compounds and therapies for the eventual development and targeting of new drug and product candidates. 

The company recently took a big step towards developing this high-potential business segment too. 

Mind Cure recently announced a $20M financing in January of this year8a

This is a big step forward for a company like Mind Cure and has the potential to establish a research program for success in an industry with so much growth potential.  

Digital Therapeutics Technology

Clinical biotech researchers will tell you one of the biggest problems in researching and developing treatments of any kind for mental health is tracking and measurement of the efficacy of the treatment. 

Mind Cure is developing a user-friendly platform call iSTRYM to much more actively work on solving that data and measurement problem. 

Formulation and Supply

Mind Cure is currently investigating and developing potential plans including the capital requirements, economics, and timelines for manufacturing, importing, and supplying traditional and
new molecular entities (NME).

Nootropic Formulations

Mind Cure has targeted nootropics as a place to stake out a share of the massive global nutritional health industry. 

A nootropic is a drug or supplement used to enhance cognitive function and fit right into Mind Cure’s aggressive growth strategy in mental wellness. 

Mind Cure’s products will be a functional mushroom powder sold under the Mind Cure brand. Within the Mind Cure brand there will be targeted products offering specific benefits to consumers with Mind Cure Energy, Focus, and Protection formulas and could be a quick path to revenues.

Mind Cure has targeted a broad range of outlets for distribution throughout the U.S and Canada.

The Company has received its Canadian Health Product Authorization Numbers (HPN), which authorizes the sale of natural products like functional mushrooms and will be ramping up sales efforts through multiple channels. 

The first physical distribution point is through Body Energy Club franchises. The Body Energy Club has 17 locations in Canada and the United States. 

After that, Mind Cure has announced it will be targeting online sales and distribution directly to consumers and could sell through Amazon, Google Shopping, eBay, Bonanza, and Walmart Marketplaces. 

The total market for just the functional mushrooms is $23 billion per year and growing, and represents a growth market opportunity.

In the end, Mind Cure is a company structured in a way to ride the mental health sector boom in multiple ways. New psychoactive drug development that targets anxiety, PTSD, depression and pain with a new class of drugs could bring new healing power in mental health-related illnesses and unlock massive profits

For investors though, the potential opportunity in Mind Cure has an extra advantage over the multi-billion-dollar success stories like Compass Pathways and Mind Medicine we mentioned above. 
The Math Of An Exponential Growth Opportunity

For investors, Mind Cure's (OTC: MCURF | CSE:MCUR) advantage is its current valuation. 
Those neuroscience companies that were featured have soared in value in the last few months.
Mind Medicine reached a value of more than $1.5 billion
The others are worth hundreds of millions each. 
Mind Cure, however, is much earlier in its growth trajectory.
Which means, even though Mind Cure shares have done well after climbing more than 200% from their IPO price last summer,
Mind Cure is still worth only a fraction of those high-flyers featured above. 
But that could change soon.  

Mind Cure just announced a C$20 million financing deal. 
After it is completed, Mind Cure (MCURF) will have around 87 million shares issued and outstanding and, at USD$0.50 per share, the total market cap would be about US$43.5 million.

That’s a fraction of what the world’s largest medicinal companies have been valued at.
Relative to Compass Pathways ($1.5 billion) and Mind Medicine ($1.6 billion), Mind Cure has exponential room to grow from here.
And with CAN$20 million in additional capital from the recently announced financing, the company could be on its way to getting up there.  
The timing couldn’t be better either as the wind is still at the back of these biotech startups.

The Simple Secret Behind History’s Greatest Investors

Wealthiest Entrepreneurs

Focus on the Future

The Simple Secret Behind History’s Greatest Investments

Today’s wealthiest entrepreneurs and investors all managed to look past the skeptics and keep their focus on the future.

Every decade has been marked with huge opportunities for those looking towards the future. 

A decade ago Bitcoin was $25 each. It’s up more than 100,000% since then.

Five years ago legal cannabis was laughable. Today it’s legal in most states and early investors walked away with fortunes. 

New psychoactive drugs are at the same stage as those fortune-making megatrends were when they were just beginning. 

The bad news is the skeptics will miss out on it all this time too. 

The good news is you don’t have to be one of those who miss out again.


That’s where Mind Cure (OTC: MCURF | CSE:MCUR) comes in because it’s just starting its growth trajectory.

The Rise Of New Mental Health Treatments

In the last few years, top medical researchers have rediscovered the positive effects of a new class of drugs and the healing power in mental health-related illnesses.

Consider a recent article from the Wall Street Journal – the investor's paper of record. It reported that this new class of drugs “can help alleviate depression, anxiety and addiction.”9

And NBC News recently proclaimed, “Therapeutic ‘trips’ may someday bring relief from addiction, anxiety, depression — and even the fear of death.”11

And it's not just the press either. 

Academia is also fully on board. Top researchers at Yale, Johns Hopkins, University of North Carolina12, and many other top universities worldwide are paving the way forward for an entirely new class of drugs that can change the way we live, how well we live – and how long we live. 

The U.S. Military has even started researching the remarkable power of this new class of drugs.

In June of 2020 the Department of Defense’s Defense Advanced Research Projects Agency (DARPA) announced it would invest $26.9 million12 into researching medicinal applications for this new class of drugs.

DARPA said its research “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.”13

The rise of neuroscience drug research is here.

There are years of growth ahead and, if this new class of drugs are as disruptive as some of the world’s top investors believe, there is exponential potential for early investors. 



Mind Cure (OTC: MCURF | CSE: MCUR) has moved quickly on multiple points of their 5 Spheres program, giving them early mover advantage and building out a strong base to grow from. 

They recently announced their research program and have a team of world-class scientific advisors.

This is a big step forward Mind Cure, as this program will focus on investigating new compound research to be used in the treatment of physical and psychological pain and related mental health illnesses. 

This allows them to start executing their research into providing safe and viable medicines, treatments and methodologies for a variety of mental health issues, under a world-class team of scientists and researchers. 



Digital Therapeutics Industry Growth Forecast 

The pace of digital therapeutics adoption is accelerating beyond earlier forecasts. 

Digital Therapeutics is the new frontier in healthcare technology and have been a steadily-rising force within the healthcare sector. 

The Digital Therapeutics Alliance defines them as “evidence-based therapeutic interventions to patients that are driven by high-quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioural conditions.”

Their increasingly proven potential as a better, more efficient, and more effective treatment option for the most costly and complex chronic physical and mental health conditions makes their broad adoption almost inevitable at this point.

The investor community is now waking up to the potential of Digital Therapeutics. 

Last year investments in healthcare startups hit $32.49 billion in a record total of 1,414 deals according to Silicon Valley Bank12b

McKinsey notes the potential of Digital Therapeutics being realized by investors when it reported, “Investors’ enthusiasm mirrors the growing demand for digital-therapeutic products and tools across the healthcare ecosystem.”


Mind Cure Health (OTC: MCURF | CSE: MCUR) recently announced their entry into Digital Therapeutics with the build-out of iSTRYM, a technology platform for mental wellness optimization and research. 

This platform will gather mental health optimization data and research, using machine learning to provide faster data to their research team, provide better data to mental health professionals worldwide and act as a hub of information for researchers and therapists. 

Mind Cure CEO Kelsey Ramsden says: 

“As a life sciences and digital therapeutics company, providing speed to market with novel therapies through deeper data analytics is a strength we are developing with iSTRYM. Further, as we build out our database for mental wellness, both therapists and individuals will get mental wellness protocols for wellness optimization and support. iSTRYM exists to become the source that individuals turn to for science-backed, personalized mental health support at scale.”

This will help solve one of the biggest problems facing research in the mental health treatment space; access to formalized protocols and data to create standard practice and procedures and for use in scientific breakthroughs. 

Both the future ATMA treatment centers and British Columbia treatment center will feed data directly into iSTRYM allowing for better treatment and new breakthroughs.
This move will give Mind Cure a direct stake in the rapidly rising Digital Therapeutics sector and complement its strategy to become a full-spectrum mental health and wellness company.


Mind Cure has released a series of announcements on new appointments, including some highly regarded individuals in the world of neuroscience drugs and therapies.

  • Kelsey Ramsden, two-time Top Female Entrepreneur in Canada, was named as Mind Cure’s new Chief Operating Officer

  • Dr. Dan Engle, a world-renowned physician in psychiatry and neurology deeply involved in new pyschoactive drug development, was appointed as an Advisor

  • Hamilton Morris, an award-winning journalist and pyschoactive drug expert, was added as an Advisor

  • Dr. Jason Wallach, a prominent researcher and academic in pyschoactive medicines, was also appointed as an Advisor

  • Dr. Wolfram Tetzlaff, a world-renowned researcher and scientist with decades of experience in neuroscience, known for his innovative and multidisciplinary approach

  • Geoff Belair, a Fintech executive with deep experience in developing and operating new and innovative technologies in highly regulated industries 

  • Jon Bier, health & wellness “industry tastemaker”

  • Dr. Ryan Hartwell, Award-Winning experimental scientist as Chief Science Officer

A strong hand to guide operations. Leading minds – and voices – in the world of psychoactive medicine and neuroscience drug R&D.

Mind Cure is assembling the right cast for neuroscience research success.



“Mind Cure believes the mental health space is ripe for innovation, and investment that could lead to major disruption in how mental health is treated.”

Mind Cure 2020

Consider Investing In Neuroscience Start Ups Now

In the end, the entire opportunity in biotech start ups is a simple one. 

The mental health care industry is long overdue for major innovation. 

Anti-depressants, many developed in the middle of the last century, have consistently proven to not be the most effective treatments or even possibly counterproductive in many cases.  

A new class of medicines have the potential to be the disruptive force that shakes up the entire mental health sector. 

And now these new start up biotech stocks have attracted the financial backing of some of the biggest money investors in the world and can truly advance clinical research in neuroscience targeted at the most promising mental health solutions. 

That final change – the surge of capital and investor awareness – has changed everything for all facets of the neuroscience focused biotechs. 

Companies like Mind Cure (OTC: MCURF | CSE: MCUR) may be positioned to ride the boom all the way to the top too. 

All the best,

Dynamic Wealth Research Team

Top 3 Biotech Stocks for 2021
Silicon Valley Bets Billions On Rise Of “Digital Therapeutics”




1 Analyst - $100 billion -
2 Mind Cure - 51+ million s/o – Feb. 1 closing price of US$0.508 – $25+ million
3 Additional Sources – Bloomberg quote -
5 ATAI Life Sciences $125 million raise -
7 Mind Med – valuation – 359 million s/o @ US$4.50 (C$6.00) - $1.61 billion
8 Mind Cure Prospectus
MMED CHART 1 From $0.338 per share on September 14, 2020, to $4.84 per share on December 11, 2020 per – a gain of 1332% per online percentage calculator at: 
NUMI CHART 2 From $0.33 a share on October 15, 2020, to $2.23 a share on December 14, 2020, per – a gain of 576% per online percentage calculator at: 
CYBN CHART 3 From $0.74 a share on November 18, 2020, to $2.39 a share on December 18, 2020, per – a gain of 223% per online percentage calculator at: 

Please see full disclaimers at applicable to all content provided by DWR , wherever published or republished:

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. (DWR) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.

DWR receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to DWR and may hire additional publishers or advertisers on behalf of the issuer. DWR retains any excess sums after expenses as its compensation. DWR may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus DWR and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.

DWR and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; DWR is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.

This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or DWR or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at where readers can review all public filings submitted by the issuer. DWR is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.